PLoS ONE (Jan 2012)

S100A9 is a biliary protein marker of disease activity in primary sclerosing cholangitis.

  • Lisa Reinhard,
  • Christian Rupp,
  • Hans-Dieter Riedel,
  • Thomas Ruppert,
  • Thomas Giese,
  • Christa Flechtenmacher,
  • Karl Heinz Weiss,
  • Petra Kloeters-Plachky,
  • Wolfgang Stremmel,
  • Peter Schirmacher,
  • Peter Sauer,
  • Daniel Nils Gotthardt

DOI
https://doi.org/10.1371/journal.pone.0029821
Journal volume & issue
Vol. 7, no. 1
p. e29821

Abstract

Read online

Background and aimsBile analysis has the potential to serve as a surrogate marker for inflammatory and neoplastic disorders of the biliary epithelium and may provide insight into biliary pathophysiology and possible diagnostic markers. We aimed to identify biliary protein markers of patients with primary sclerosing cholangitis (PSC) by a proteomic approach.MethodsBile duct-derived bile samples were collected from PSC patients (n = 45) or patients with choledocholithiasis (n = 24, the control group). Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed to analyse the proteins, 2-D-gel patterns were compared by densitometry, and brush cytology specimens were analysed by RT-PCR.ResultsA reference bile-duct bile proteome was established in the control group without signs of inflammation or maligancy comprising a total of 379 non-redundant biliary proteins; 21% were of unknown function and 24% had been previously described in serum. In PSC patients, the biliary S100A9 expression was elevated 95-fold (pConclusionsThe bile-duct bile proteome is complex and its analysis might enhance the understanding of cholestatic liver disease. Biliary S100A9 levels may be a useful marker for PSC activity, and its implication in inflammation and carcinogenesis warrants further investigation.